Licence extension for Januvia

Januvia (sitagliptin) is now licensed for first-line treatment of type II diabetes when metformin is contraindicated or not tolerated. The recommended dose is 100mg once daily.

View Januvia drug record

Further information: Merck

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Direct-acting oral anticoagulants set for wider use under NHS deal

Direct-acting oral anticoagulants set for wider use under NHS deal

More than half a million more people will be able to...

NICE recommends SGLT2 inhibitors for chronic kidney disease

NICE recommends SGLT2 inhibitors for chronic kidney disease

Updated NICE guidance on type II diabetes recommends...